Details for Patent: 11,400,092

Which drugs does patent 11,400,092 protect, and when does it expire?

Patent 11,400,092 protects INREBIC and is included in one NDA.

This patent has thirteen patent family members in thirteen countries.

Summary for Patent: 11,400,092

Patent landscape, scope, and claims:

Title:	Methods of treating myeloproliferative disorders
Abstract:	The present disclosure provides methods of mitigating thiamine deficiency.
Inventor(s):	Berry; Tymara (Morristown, NJ), Hood; John (Del Mar, CA), Jamieson; Catriona (La Jolla, CA), Scribner; Curtis L. (Oakland, CA)
Assignee:	Impact Biomedicines, Inc. (Summit, NJ)
Application Number:	17/560,373
Patent Claim Types: see list of patent claims	Use; Delivery;

Drugs Protected by US Patent 11,400,092

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Bristol-myers	INREBIC	fedratinib hydrochloride	CAPSULE;ORAL	212327-001	Aug 16, 2019		RX	Yes	Yes	11,400,092					TREATING ADULT PATIENTS WITH INTERMEDIATE-2 OR HIGH-RISK PRIMARY OR SECONDARY MYELOFIBROSIS, MONITORING THIAMINE LEVELS AND ADMINISTERING THIAMINE OR A THIAMINE EQUIVALENT

International Family Members for US Patent 11,400,092

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2019346521
Brazil	112021005518
Chile	2021000744